Scientists scan brains to see if new drug hits target in schizophrenia
NCT ID NCT07423546
Summary
This study aims to understand how an experimental drug called Cobenfy affects brain chemistry in people with schizophrenia. Twelve participants will receive one of three doses for five weeks and undergo special brain scans before and after treatment. The main goal is to measure if and how Cobenfy changes dopamine activity in specific brain regions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA 1 (DISORDER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.